20/20 Bio Labs

Coming – October 21

What If a Blood Test Could Tell You What’s Coming?

Date and Time

October 21

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

From Cancer Detection to Longevity: The Emerging Opportunity in AI-Powered Blood Testing

For generations, blood tests have primarily told physicians what is happening in the body today. Advances in biomarkers, artificial intelligence, and longitudinal data are creating the potential to do something much more powerful: identify disease and health risks earlier, potentially before symptoms appear.

20/20 BioLabs (NASDAQ: AIDX) is pursuing that opportunity across two enormous healthcare markets.

Its OneTest™ for Cancer combines multiple protein biomarkers with machine learning to help identify signals associated with multiple cancers. The company has also expanded its platform into longevity and chronic-disease risk, using blood-based biomarkers and AI to provide insight into risks associated with cardiovascular disease, diabetes, dementia, and other age-related conditions.

Join 20/20 BioLabs President & CEO Jonathan Cohen for a Fireside Chat exploring:
  • Why blood-based early detection may be entering an important new era
  • How AI and longitudinal biomarker data could make testing increasingly valuable over time
  • The connection between cancer detection, chronic disease, and longevity
  • How 20/20 BioLabs plans to scale its technology and commercial reach
  • Recent regulatory, reimbursement, and market developments that could accelerate adoption
  • The milestones ahead that could shape the company’s next stage of growth

This is a conversation about more than two tests. It is about whether the familiar blood test can become an early-warning system for human health, and what that could mean for patients, healthcare, and the emerging market for predictive diagnostics.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.